Myriad Genetics, Inc. (MYGN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Biotechnology	824.50M	837.60M	753.20M	678.40M	690.60M
Biotechnology Growth	-1.56%	11.21%	11.03%	-1.77%	-
Total	824.50M	837.60M	753.20M	678.40M	690.60M
Total Growth	-1.56%	11.21%	11.03%	-1.77%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Rest of world	56.50M	68.10M	81.50M	86.90M	-
Rest of world Growth	-17.03%	-16.44%	-6.21%	-	-
United States	768.00M	769.50M	671.70M	591.50M	-
United States Growth	-0.19%	14.56%	13.56%	-	-
Total	824.50M	837.60M	753.20M	678.40M	-
Total Growth	-1.56%	11.21%	11.03%	-	-

Data Source: S&P Global Market Intelligence Last updated: Feb 24, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 23, 2026

Data Sources Report a data error